SCHEMBL25449359

SCHEMBL25449359

CC(C)(C)C(=O)Nc1ncc2cc(C(C)(C)C)ccc2n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA1 P30542 2/20 0.43
▸ PIK3CA P42336 1/20 0.42
▸ BRAF P15056 3/20 0.41
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ TRPV1 Q8NER1 1/20 0.40
▸ POLB P06746 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ LCK P06239 1/20 0.38
▸ ABL1 P00519 1/20 0.37
▸ LRRK2 Q5S007 1/20 0.37
▸ SMN1; SMN2 Q16637 3/20 0.37
▸ MAP3K5 Q99683 1/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ TP53 P04637 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ NPC1 O15118 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12755258 0.87 PIK3CA (0.54) ADORA1PIK3CABRAFMEN1KMT2A
SCHEMBL21864816 0.84 SYK (0.44) ADORA1PIK3CABRAFMEN1KMT2A
SCHEMBL10828998 0.84 KMT2A (0.46) ADORA1PIK3CABRAFMEN1KMT2A
SCHEMBL21864813 0.83 MAPT (0.46) ADORA1PIK3CABRAFMEN1KMT2A
SCHEMBL30216052 0.83 MAPT (0.46) ADORA1PIK3CABRAFMEN1KMT2A
SCHEMBL25456203 0.83 BRAF (0.35) ADORA1PIK3CABRAFMEN1KMT2A
SCHEMBL25449364 0.79 LCK (0.41) BRAFLCKSCN10A
SCHEMBL25898917 0.78 MAPT (0.52) ADORA1BRAFMEN1KMT2ATRPV1
SCHEMBL21864818 0.75 DGAT1 (0.41) ADORA1PIK3CAPOLB
SCHEMBL30161251 0.75 DGAT1 (0.41) ADORA1PIK3CAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230143059-A1 GCN2 MODULATOR COMPOUNDS Alesta Therapeutics BV (NL) 2023-05-11 — — US disclosed
US-20230143059-A1 GCN2 MODULATOR COMPOUNDS Alesta Therapeutics BV (NL) 2023-05-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230143059-A1 GCN2 MODULATOR COMPOUNDS EIF2AK4, GPR119, GCN1 ADORA1 1458/4885PIK3CA 2491/4885BRAF 3070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback